Novo Nordisk A S (NONOF) SEC Filings — 2025
36 SEC filings for Novo Nordisk A S (NONOF) in 2025.
Filings
- Novo Nordisk A S 6-K Filing — 6-K · Dec 23, 2025
- Novo Nordisk's Amycretin Shows Strong Weight Loss in Diabetes Trial — 6-K · Nov 25, 2025
- Novo Nordisk Alzheimer's Trials Fail to Meet Primary Endpoint — 6-K · Nov 24, 2025
- Novo Nordisk Discloses Insider Share Transactions — 6-K · Nov 17, 2025
- Novo Nordisk A S 6-K Filing — 6-K · Nov 14, 2025
- Novo Nordisk A S 6-K Filing — 6-K · Nov 12, 2025
- Novo Nordisk to Lower GLP-1 Prices for US Medicare — 6-K · Nov 7, 2025
- Novo Nordisk A S 6-K Filing — 6-K · Nov 5, 2025
- Novo Nordisk proposes Metsera acquisition — 6-K · Oct 30, 2025
- Novo Nordisk Calls EGM for Board Elections — 6-K · Oct 21, 2025
- Novo Nordisk to Acquire Akero Therapeutics for MASH Portfolio — 6-K · Oct 9, 2025
- Novo Nordisk to cut 9,000 jobs for growth reinvestment — 6-K · Sep 10, 2025
- Novo Nordisk Discloses Insider Trading Activity — 6-K · Aug 19, 2025
- Novo Nordisk's Wegovy Approved for MASH in US — 6-K · Aug 18, 2025
- Novo Nordisk Discloses Insider Share Transactions — 6-K · Aug 14, 2025
- Novo Nordisk Discloses Insider Share Transactions — 6-K · Aug 8, 2025
- Novo Nordisk Files Routine 6-K Report — 6-K · Aug 6, 2025
- Novo Nordisk Responds to TRC Capital Mini-Tender Offer — 6-K · Aug 4, 2025
- Novo Nordisk Lowers 2025 Outlook Despite Strong H1 Growth — 6-K · Jul 29, 2025
- Novo Nordisk Advances Amycretin to Phase 3 for Weight Management — 6-K · Jun 13, 2025
- Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down — 6-K · May 16, 2025
- Novo Nordisk Discloses Insider Share Transactions — 6-K · May 9, 2025
- Novo Nordisk Files Q1 2025 Report — 6-K · May 7, 2025
- Novo Nordisk Executive VP Camilla Sylvest Departs — 6-K · Apr 3, 2025
- Novo Nordisk Reports Strong 2024 Growth at AGM — 6-K · Mar 31, 2025
- Novo Nordisk's CagriSema Shows Superior Weight Loss in Phase 3 Trial — 6-K · Mar 10, 2025
- Novo Nordisk Annual General Meeting Set for March 27 — 6-K · Feb 27, 2025
- Novo Nordisk Discloses Insider Trading Activity — 6-K · Feb 7, 2025
- Novo Nordisk Discloses Insider Share Transactions — 6-K · Feb 6, 2025
- Novo Nordisk Files 2024 Annual Report — 20-F · Feb 5, 2025
- Novo Nordisk Initiates Share Repurchase Program — 6-K · Feb 4, 2025
- Novo Nordisk Initiates Share Repurchase Program — 6-K · Jan 27, 2025
- Novo Nordisk Obesity Drug Amycretin Shows Promise in Trial — 6-K · Jan 24, 2025
- Novo Nordisk Completes Share Repurchase Program — 6-K · Jan 21, 2025
- Novo Nordisk Semaglutide Shows Strong Weight Loss in Obesity Trial — 6-K · Jan 17, 2025
- Novo Nordisk Completes DKK 1B Share Repurchase — 6-K · Jan 15, 2025